A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?

J Cancer Res Clin Oncol. 2021 Oct;147(10):3135-3137. doi: 10.1007/s00432-021-03647-x. Epub 2021 Apr 26.

Alessandro Leonetti^#^{1

2

3}, Daniela Carbone^#^{3

4}, Alessandro Gregori³, Marcello Tiseo^{1

2}, Godefridus J Peters^{3

5}, Dongmei Deng⁶, Elisa Giovannetti^{7

8}

¹ Department of Medicine and Surgery, University of Parma, Parma, Italy.
² Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
³ Department of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam (CCA), Location VUmc, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
⁴ Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Palermo, Italy.
⁵ Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
⁶ Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.
⁷ Department of Medical Oncology, Amsterdam UMC, VU University, Cancer Center Amsterdam (CCA), Location VUmc, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. e.giovannetti@amsterdamumc.nl.
⁸ Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisana per la Scienza (FPS), Pisa, Italy. e.giovannetti@amsterdamumc.nl.

^# Contributed equally.

No abstract available

Publication types